https://www.selleckchem.com/pr....oducts/Vorinostat-sa
part/none 47%) who received all of their treatment at a SCC. After adjusting for sociodemographic and clinical factors, receiving all inpatient cancer treatment at a SCC was associated with superior overall survival (EWS HR 0.49, CI 0.37-0.67; OS HR 0.78, CI 0.63-0.97). Our results suggest that treatment for EWS and OS at a SCC is associated with significantly improved survival even after adjustment for known prognostic factors. The superior survival among those treated at SCCs may be due to having greater access to clinical tri
Like
Comment
Share
